-
| CurrencyCode | EUR |
|---|---|
| ISIN | US5171251003 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | F |
| Market Cap | 162M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.91 |
| Dividend Yield | None |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ZA71.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025